Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)

9 października 2026 zaktualizowane przez: EyeBiotech Ltd.

A 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Single-masked Comparative Safety and Preliminary Efficacy Study of Intravitreal (IVT) Remigromig in a Mixed Population of Participants With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

33

Faza

  • Faza 2
  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Caba, Argentyna, 1023
        • Caba, Argentina
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentyna, C1121ABB
        • Ciudad Autonoma Buenos Aires
    • PR
      • Arecibo, PR, Portoryko, 00612
        • Arecibo, PR
    • Arizona
      • Phoenix, Arizona, Stany Zjednoczone, 85032
        • Phoenix, AZ
    • California
      • Bakersfield, California, Stany Zjednoczone, 93309
        • Bakersfield, CA
      • Modesto, California, Stany Zjednoczone, 95356
        • Modesto, CA
      • Mountain View, California, Stany Zjednoczone, 94040
        • Mountain View, CA
      • Sacramento, California, Stany Zjednoczone, 95825
        • Sacramento, CA
      • Sacramento, California, Stany Zjednoczone, 95841
        • Sacramento, CA
    • Colorado
      • Colorado Springs, Colorado, Stany Zjednoczone, 80909
        • Colorado Springs, Colorado
      • Lakewood, Colorado, Stany Zjednoczone, 80288
        • Lakewood, CO
    • Florida
      • Pompano Beach, Florida, Stany Zjednoczone, 33064
        • Pompano Beach
    • Illinois
      • Lemont, Illinois, Stany Zjednoczone, 60439
        • Lemont, NV
    • Maryland
      • Hagerstown, Maryland, Stany Zjednoczone, 21740
        • Hagerstown, MD
    • Nevada
      • Reno, Nevada, Stany Zjednoczone, 89502
        • Reno, NV
    • South Carolina
      • West Columbia, South Carolina, Stany Zjednoczone, 29169
        • West Columbia, SC
    • Tennessee
      • Germantown, Tennessee, Stany Zjednoczone, 38138
        • Germantown, TN
      • Knoxville, Tennessee, Stany Zjednoczone, 37922
        • Knoxville, TN
      • Nashville, Tennessee, Stany Zjednoczone, 37203
        • Nashville, TN
    • Texas
      • Abilene, Texas, Stany Zjednoczone, 79606
        • Abilene, TX
      • Amarillo, Texas, Stany Zjednoczone, 79109
        • Amarillo, TX
      • Austin, Texas, Stany Zjednoczone, 78705
        • Austin, TX
      • Bellaire, Texas, Stany Zjednoczone, 77401
        • Bellaire, TX
      • Dallas, Texas, Stany Zjednoczone, 75231
        • Dallas, TX
      • Katy, Texas, Stany Zjednoczone, 77494
        • Katy, TX
      • McAllen, Texas, Stany Zjednoczone, 78503
        • McAllen, TX
      • Plano, Texas, Stany Zjednoczone, 75075
        • Plano, TX
      • Round Rock, Texas, Stany Zjednoczone, 78681
        • Round Rock, TX
      • San Antonio, Texas, Stany Zjednoczone, 78240
        • San Antonio, TX
      • The Woodlands, Texas, Stany Zjednoczone, 77384
        • The Woodlands, TX
      • London, Zjednoczone Królestwo, W1G7LB
        • London, UK
    • England
      • London, England, Zjednoczone Królestwo, NW10 7NS
        • London, England

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

50 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
  • DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age
  • Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMD patients can be either treatment naïve or treatment experienced.
  • DME patients must have vision loss in the study eye
  • NVAMD patients can be either treatment-naïve or treatment experienced with vision loss in the study eye

Exclusion Criteria:

  • Be pregnant or breastfeeding
  • History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening
  • Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening
  • Any other condition except for DME or NVAMD or that could affect interpretation of study assessments

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Zadanie sekwencyjne
  • Maskowanie: Potroić

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Dose 1

Part 1 MAD Portion Dose 1 - Low Dose

Remigromig is a humanized antibody formulated for IVT administration

Inne nazwy:
  • EYE103
Eksperymentalny: Dose 2

Part 1 MAD Portion Dose 2 - Low-Mid Dose

Remigromig is a humanized antibody formulated for IVT administration

Inne nazwy:
  • EYE103
Eksperymentalny: Dose 3

Part 1 MAD Portion Dose 3 - Mid-High Dose

Remigromig is a humanized antibody formulated for IVT administration

Inne nazwy:
  • EYE103
Eksperymentalny: Dose 4

Part 1 MAD Portion Dose 4 - High Dose

Remigromig is a humanized antibody formulated for IVT administration

Inne nazwy:
  • EYE103
Eksperymentalny: DME Medium Dose

Part 2 Naïve DME monotherapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

Inne nazwy:
  • EYE103
Eksperymentalny: DME High Dose

Part 2 Naïve DME monotherapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

Inne nazwy:
  • EYE103
Eksperymentalny: Naïve NVAMD Medium Dose

Part 2 Naïve NVAMD combination therapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

Inne nazwy:
  • EYE103
Eksperymentalny: Naïve NVAMD High Dose

Part 2 Naïve NVAMD combination therapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

Inne nazwy:
  • EYE103
Eksperymentalny: Experienced NVAMD Medium Dose

Part 2 Experienced NVAMD combination therapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

Inne nazwy:
  • EYE103
Eksperymentalny: Experienced NVAMD High Dose

Part 2 Experienced NVAMD combination therapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

Inne nazwy:
  • EYE103

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
Ramy czasowe: Up to approximately 12 weeks

Systemic DLTs are defined as a Grade III (severe), IV (life threatening) or V (death related to adverse event) toxicities as defined in the National Cancer Institute (NCI) Common Toxicity Criteria, or any significant severe toxicity deemed related to study drug by the principal investigator. Ocular DLTs are defined as: loss of 4 or more lines of visual acuity, clinically significant inflammation, increase of intra-ocular pressure (IOP) from baseline of > or =15 mmHg, accelerated formation of cataract, other severe ocular abnormalities not usually seen in subjects with the condition under study, or significant retinal or choroidal vascular abnormalities seen on fluorescein angiogram deemed related to study drug by the investigator.

Up to approximately 12 weeks
Number of Participants Who Experienced an Adverse Event (AE)
Ramy czasowe: Up to approximately 12 weeks

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to approximately 12 weeks
Number of Participants Who Experienced a Serious Adverse Event (SAE)
Ramy czasowe: Up to approximately 24 weeks

An SAE is defined as any adverse experience occurring at any dose that results in any of the following outcomes: Results in death; Is life threatening (immediate risk of death); results in persistent or significant disability/incapacity; requires participant hospitalization or prolongs participant hospitalization; or results in a congenital anomaly/birth defect in a neonate/infant

Up to approximately 24 weeks
Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments
Ramy czasowe: Baseline and Week 12

Clinical laboratory tests, including overnight fasting serum chemistry, lipid panel, hematology, and coagulation panel were collected at baseline and at week 12 study visit. Any laboratory test result considered by the investigator to be clinically significant was considered to be an AE. Clinically significant abnormal values were followed up until repeat test results return to normal, stabilize, or are no longer clinically significant.

Baseline and Week 12
Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants
Ramy czasowe: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Baseline and Week 12
Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants
Ramy czasowe: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Baseline and Week 12

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants
Ramy czasowe: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants
Ramy czasowe: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants
Ramy czasowe: Baseline and 12 weeks

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Baseline and 12 weeks
Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants
Ramy czasowe: Baseline and 12 weeks

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Baseline and 12 weeks
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants
Ramy czasowe: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants
Ramy czasowe: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants
Ramy czasowe: Baseline and Week 12

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants
Ramy czasowe: Baseline and Week 12

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Baseline and Week 12

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

12 czerwca 2023

Zakończenie podstawowe (Rzeczywisty)

26 sierpnia 2024

Ukończenie studiów (Rzeczywisty)

26 sierpnia 2024

Daty rejestracji na studia

Pierwszy przesłany

14 czerwca 2023

Pierwszy przesłany, który spełnia kryteria kontroli jakości

14 czerwca 2023

Pierwszy wysłany (Rzeczywisty)

26 czerwca 2023

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

3 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

9 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • EYE103-101
  • MK-3000-003 (Inny identyfikator: Merck)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .